Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface

Journal: Cancer Research

Published: 2019-11-01

DOI: 10.1158/0008-5472.can-19-1112

Affiliations: 20

Authors: 33

Go to article
Institutions Share
Lowy Cancer Research Centre, Australia 0.46
ACRF Rational Drug Discovery Centre, SVI, Australia 0.09
Department of Pharmacy and Biotechnology, UNIBO, Italy 0.06
Institute of Molecular Medicine, MLU, Germany 0.06
Children‘s Hospital Cologne Amsterdamer, Germany 0.05
Department of Biochemistry and Molecular Biology, UniMelb, Australia 0.03
Bio21 Molecular Science and Biotechnology Institute (Bio21 Institute), UniMelb, Australia 0.03
School of Women's and Children's Health (SPHCM), UNSW Sydney, Australia 0.03
UCSF Department of Pediatrics, United States of America (USA) 0.03
UCSF Helen Diller Family Comprehensive Cancer Center, United States of America (USA) 0.03
Mayo Clinic Department of Biochemistry and Molecular Biology, United States of America (USA) 0.02
Mayo Clinic Comprehensive Cancer Center, United States of America (USA) 0.02
Mayo Clinic Center for Individualized Medicine (CIM), United States of America (USA) 0.02
Australian Centre for NanoMedicine (ACN), UNSW Sydney, Australia 0.02
Max Planck Institute for Metabolism Research, Germany 0.02
Prince of Wales Private Hospital, Australia 0.02
School of Biomedical Engineering, UTS, Australia 0.01
School of Life Sciences and Technology, Tongji University, China 0.01
Kids Cancer Centre, Sydney Children's Hospitals Network, Australia 0.01

Return